Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of reagent kit in accordance with ASMT/CYP1A2 molecules to forecasting clinical prognosis and immunity characteristics of solid tumors

A technology of CYP1A2 and reagent kit, which is applied in the direction of microbial measurement/inspection, biochemical equipment and methods, etc., can solve the problem of no molecular label, etc., and achieve the effect of improving the therapeutic effect

Active Publication Date: 2019-04-12
SUN YAT SEN UNIV CANCER CENT
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are currently no molecular tags for relevant applications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of reagent kit in accordance with ASMT/CYP1A2 molecules to forecasting clinical prognosis and immunity characteristics of solid tumors
  • Application of reagent kit in accordance with ASMT/CYP1A2 molecules to forecasting clinical prognosis and immunity characteristics of solid tumors
  • Application of reagent kit in accordance with ASMT/CYP1A2 molecules to forecasting clinical prognosis and immunity characteristics of solid tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] The present invention will be further described below in conjunction with specific experiments. It should be understood that the following content is only used to illustrate the present invention and is not intended to limit the protection scope of the present invention.

[0022] ASMT / CYP1A2 ratio in different solid tumors

[0023] By analyzing 14 solid tumors (bladder cancer, breast cancer, cervical cancer, colon cancer, head and neck squamous cell carcinoma, kidney cancer, hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, prostate cancer, skin cancer) in the public database TCGA , gastric cancer and thyroid cancer) transcriptome and genome data of a total of 6,658 tumor samples, and calculate the ratio of ASMT to CYP1A2 in each tumor tissue (ASMT / CYP1A2), which reflects the level of melatonin in the tumor tissue. The ASMT / CYP1A2 results of each tumor tissue were divided into High Index and Low Index ( figure 1 )Group.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a reagent kit in accordance with ASMT / CYP1A2 molecules to forecasting clinical prognosis and immunity characteristics of solid tumors. The inventor performs bioinformation analysis of large samples through researching transcriptomes and genome data of 6658 tumor samples in all of 14 kinds of entity tumors, the relationship of the ratio level of ASMT / CYP1A2and clinical prognosis, tumor mutation level and tumor neoantigen load of patients in different entity tumors is confirmed, wherein the clinical prognosis of the patients suffering from breast cancerand gastric cancer in a High Index group is more considerable; the multifactor analysis result shows that the result of ASMT / CYP1A2 is an independent forecasting index of the clinical prognosis of the tumor patients; in addition, in patients suffering from bladder cancer, breast cancer and prostatic cancer, the prognosis of patients in a Low Index group is poor, but more mutational load and / or tumor neoantigen exists, which prompts that the patients in the Low Index group can obtain benefits from immunotherapy possibly.

Description

technical field [0001] The present invention relates to markers and applications for predicting clinical prognosis of solid tumors, immune body mutation level and / or neoantigen load. Background technique [0002] Tumor is the third major disease threatening human health. In 2018, there were about 18.19 million new cancer cases and 9.6 million cancer deaths worldwide. The incidence of tumors has shown a downward trend year by year with the advancement of medical technology and the enhancement of people's awareness of cancer prevention, while the mortality rate of some cancers is still high. Therefore, it is very important to accurately evaluate the prognosis of tumor patients and choose the appropriate treatment plan according to their characteristics. In recent years, immunotherapy has developed rapidly and has become the fourth major anti-cancer weapon after surgery, radiotherapy and chemotherapy, and targeted therapy. Relevant immunotherapy drugs, such as anti-PD-1 mono...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886
CPCC12Q1/6886C12Q2600/106C12Q2600/118C12Q2600/158
Inventor 孙颖陈雨沛吕佳蔚郑子奇
Owner SUN YAT SEN UNIV CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com